South Korea · Delayed Price · Currency is KRW REMEDI Statistics
Total Valuation
REMEDI has a market cap or net worth of KRW 75.34 billion. The enterprise value is 84.99 billion.
| Market Cap | 75.34B |
| Enterprise Value | 84.99B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
REMEDI has 7.63 million shares outstanding.
| Current Share Class | 7.63M |
| Shares Outstanding | 7.63M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 52.39% |
| Owned by Institutions (%) | n/a |
| Float | 3.63M |
Valuation Ratios
The trailing PE ratio is 7.69.
| PE Ratio | 7.69 |
| Forward PE | n/a |
| PS Ratio | 3.74 |
| PB Ratio | 5.34 |
| P/TBV Ratio | 5.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 10.36 |
| EV / Sales | 4.22 |
| EV / EBITDA | 11.83 |
| EV / EBIT | 13.46 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.51, with a Debt / Equity ratio of 0.87.
| Current Ratio | 1.51 |
| Quick Ratio | 0.92 |
| Debt / Equity | 0.87 |
| Debt / EBITDA | 1.71 |
| Debt / FCF | -6.57 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 33.47% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 394.92M |
| Profits Per Employee | 160.89M |
| Employee Count | 51 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.17B |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 5,877,664 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, REMEDI had revenue of KRW 20.14 billion and earned 8.21 billion in profits. Earnings per share was 1,284.00.
| Revenue | 20.14B |
| Gross Profit | 12.43B |
| Operating Income | 6.32B |
| Pretax Income | 6.20B |
| Net Income | 8.21B |
| EBITDA | 7.18B |
| EBIT | 6.32B |
| Earnings Per Share (EPS) | 1,284.00 |
Balance Sheet
The company has 2.90 billion in cash and 12.30 billion in debt, with a net cash position of -9.40 billion or -1,232.95 per share.
| Cash & Cash Equivalents | 2.90B |
| Total Debt | 12.30B |
| Net Cash | -9.40B |
| Net Cash Per Share | -1,232.95 |
| Equity (Book Value) | 14.11B |
| Book Value Per Share | 2,169.32 |
| Working Capital | 5.54B |
Cash Flow
In the last 12 months, operating cash flow was -1.33 billion and capital expenditures -542.77 million, giving a free cash flow of -1.87 billion.
| Operating Cash Flow | -1.33B |
| Capital Expenditures | -542.77M |
| Depreciation & Amortization | 867.52M |
| Net Borrowing | 3.45B |
| Free Cash Flow | -1.87B |
| FCF Per Share | -245.65 |
Margins
Gross margin is 61.70%, with operating and profit margins of 31.36% and 40.74%.
| Gross Margin | 61.70% |
| Operating Margin | 31.36% |
| Pretax Margin | 30.80% |
| Profit Margin | 40.74% |
| EBITDA Margin | 35.66% |
| EBIT Margin | 31.36% |
| FCF Margin | n/a |
Dividends & Yields
REMEDI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 10.89% |
| FCF Yield | -2.49% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REMEDI has an Altman Z-Score of 1.49 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.49 |
| Piotroski F-Score | 1 |